ArtNr |
LEIN-LT400-25mg |
Hersteller |
Leinco Technologies
|
Menge |
25 mg |
Quantity options |
1 mg
100 mg
25 mg
5 mg
50 mg
Custom
|
Kategorie |
|
Typ |
Antibody Primary |
Applikationen |
WB, FC, IP, ELISA, other |
Clon |
A4.6.1 |
Specific against |
Human (Homo sapiens) |
Host |
Human |
Purity |
≥95% monomer by analytical SEC |
Citations |
1. Pazdur, R. et al. (2018) Clin Cancer Res. 24(18):4365-70. |
NCBI |
7422 |
ECLASS 10.1 |
32160702 |
ECLASS 11.0 |
32160702 |
UNSPSC |
12352203 |
Versandbedingung |
Gekühlt |
Lieferbar |
|
Manufacturer - Applications |
Quality Tested by Leinco FC The suggested concentration for Adalimumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. WB ELISA |
Manufacturer - Category |
Recombinant Antibodies>Biosimilar Recombinant Antibodies |
Manufacturer - Targets |
VEGF |
Country of Origin |
USA |
Shipping Temperature |
2 - 8°C Wet Ice |
Storage Conditions |
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
Product Description |
Bevacizumab is a monoclonal antibody that specifically recognizes vascular endothelial growth factor (VEGF). VEGF is a growth factor that participates in angiogenesis, vasculogenesis, and endothelial cell growth. It facilitates endothelial cell proliferation, cell migration, and the permeabilization of blood vessels. In addition, VEGF inhibits apoptosis. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the regression of tumor vascularization, normalization of remaining tumor vasculature, and inhibition of the formation of new tumor vasculature, thus inhibiting tumor growth.1 Anti-Human VEGF (Bevacizumab) utilizes the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research projects. |
Background |
Bevacizumab is a monoclonal antibody that specifically recognizes vascular endothelial growth factor (VEGF). VEGF is a growth factor that participates in angiogenesis, vasculogenesis, and endothelial cell growth. It facilitates endothelial cell proliferation, cell migration, and the permeabilization of blood vessels. In addition, VEGF inhibits apoptosis. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the regression of tumor vascularization, normalization of remaining tumor vasculature, and inhibition of the formation of new tumor vasculature, thus inhibiting tumor growth.1 Anti-Human VEGF (Bevacizumab) utilizes the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research projects. |
Pathogen Testing |
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. |
Other Applications Reported In Literature |
B N IP |
PubMed |
VEGF |
Manufacturer - Expression host |
HEK-293 |
Manufacturer - Specificity |
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Bevacizumab. Bevacizumab recognizes both native and reduced human VEGF (isoform 165). This product is for research use only. |
FC Effector Activity |
Active |
RRID |
AB_2893954 |
Concentration |
≥ 5.0 mg/ml |
Formulation |
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. |
Product Preparation |
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. |
Antigen Distribution |
VEGF is widely expressed in the thyroid, prostate, and various other tissues. |
Immunogen |
Recombinant human VEGF. |
Regulatory Status |
Research Use Only (RUO). Non-Therapeutic. |
Additonal Information |
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. |
Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.
Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.